from Q2 2010 to Q3 2025

Taxonomy & unit: us-gaap: USD
Description: The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary: ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Cost of Revenue history and change rate from Q2 2010 to Q3 2025.
ELITE PHARMACEUTICALS INC /NV/ Cost of Revenue for the quarter ending 30 Sep 2025 was $22,248,671, a 108% increase year-over-year.
ELITE PHARMACEUTICALS INC /NV/ Cost of Revenue for the twelve months ending 30 Sep 2025 was $58,179,870, a 48% increase year-over-year.
ELITE PHARMACEUTICALS INC /NV/ annual Cost of Revenue for 2024 was $43,957,274, a 45% increase from 2023.
ELITE PHARMACEUTICALS INC /NV/ annual Cost of Revenue for 2023 was $30,268,025, a 72% increase from 2022.
ELITE PHARMACEUTICALS INC /NV/ annual Cost of Revenue for 2022 was $17,561,093, a 0.54% increase from 2021.
Source SEC data: View on sec.gov

Cost of Revenue, Trailing 12 Months (USD)

Cost of Revenue, Quarterly (USD)

Cost of Revenue, YoY Quarterly Change (%)

Cost of Revenue, Annual (USD)

Cost of Revenue, YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Cost of Revenue (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$58,179,870	$22,248,671	+$11,565,754	+108%	01 Jul 2025	30 Sep 2025	10-Q	14 Nov 2025	2026	Q2
Q2 2025	$46,614,116	$12,985,127	+$2,656,842	+26%	01 Apr 2025	30 Jun 2025	10-Q	14 Aug 2025	2026	Q1
Q1 2025	$43,957,274	$14,701,165	+$4,870,494	+50%	01 Jan 2025	31 Mar 2025	10-K	30 Jun 2025	2025	FY
Q4 2024	$39,086,780	$8,244,907	-$252,820	-3%	01 Oct 2024	31 Dec 2024	10-Q	13 Feb 2025	2025	Q3
Q3 2024	$39,339,600	$10,682,917	+$2,972,811	+39%	01 Jul 2024	30 Sep 2024	10-Q	14 Nov 2025	2026	Q2
Q2 2024	$36,366,789	$10,328,285	+$6,098,764	+144%	01 Apr 2024	30 Jun 2024	10-Q	14 Aug 2025	2026	Q1
Q1 2024	$30,268,025	$9,830,671	+$5,036,809	+105%	01 Jan 2024	31 Mar 2024	10-K	30 Jun 2025	2025	FY
Q4 2023	$25,231,216	$8,497,727	+$4,166,886	+96%	01 Oct 2023	31 Dec 2023	10-Q	13 Feb 2025	2025	Q3
Q3 2023	$21,064,330	$7,710,106	+$2,948,777	+62%	01 Jul 2023	30 Sep 2023	10-Q	14 Nov 2024	2025	Q2
Q2 2023	$18,115,553	$4,229,521	+$554,460	+15%	01 Apr 2023	30 Jun 2023	10-Q	14 Aug 2024	2025	Q1
Q1 2023	$17,561,093	$4,793,862	+$577,803	+14%	01 Jan 2023	31 Mar 2023	10-K	01 Jul 2024	2024	FY
Q4 2022	$16,983,290	$4,330,841	-$626,309	-13%	01 Oct 2022	31 Dec 2022	10-Q	14 Feb 2024	2024	Q3
Q3 2022	$17,609,599	$4,761,329	-$28,963	-0.6%	01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2023	2024	Q2
Q2 2022	$17,638,562	$3,675,061	+$171,799	+4.9%	01 Apr 2022	30 Jun 2022	10-Q	14 Aug 2023	2024	Q1
Q1 2022	$17,466,763	$4,216,059	+$1,686,469	+67%	01 Jan 2022	31 Mar 2022	10-K	29 Jun 2023	2023	FY
Q4 2021	$15,780,294	$4,957,150	+$2,313,975	+88%	01 Oct 2021	31 Dec 2021	10-Q	14 Feb 2023	2023	Q3
Q3 2021	$13,466,319	$4,790,292	+$1,011,796	+27%	01 Jul 2021	30 Sep 2021	10-Q	14 Nov 2022	2023	Q2
Q2 2021	$12,454,523	$3,503,262	-$1,059,088	-23%	01 Apr 2021	30 Jun 2021	10-Q	15 Aug 2022	2023	Q1
Q1 2021	$13,513,611	$2,529,590	+$43,653	+1.8%	01 Jan 2021	31 Mar 2021	10-K	29 Jun 2022	2022	FY
Q4 2020	$13,469,958	$2,643,175	+$479,799	+22%	01 Oct 2020	31 Dec 2020	10-Q	14 Feb 2022	2022	Q3
Q3 2020	$12,990,159	$3,778,496	+$472,240	+14%	01 Jul 2020	30 Sep 2020	10-Q	15 Nov 2021	2022	Q2
Q2 2020	$12,517,919	$4,562,350	+$2,502,064	+121%	01 Apr 2020	30 Jun 2020	10-Q	16 Aug 2021	2022	Q1
Q1 2020	$10,015,855	$2,485,937	+$1,675,045	+207%	01 Jan 2020	31 Mar 2020	10-K	14 Jun 2021	2021	FY
Q4 2019	$8,340,810	$2,163,376	+$392,240	+22%	01 Oct 2019	31 Dec 2019	10-Q	16 Feb 2021	2021	Q3
Q3 2019	$7,948,570	$3,306,256	+$2,763,705	+509%	01 Jul 2019	30 Sep 2019	10-Q	16 Nov 2020	2021	Q2
Q2 2019	$5,184,865	$2,060,286	+$483,887	+31%	01 Apr 2019	30 Jun 2019	10-Q	14 Aug 2020	2021	Q1
Q1 2019	$4,700,978	$810,892	+$349,892	+76%	01 Jan 2019	31 Mar 2019	10-K	29 Jun 2020	2020	FY
Q4 2018	$4,351,086	$1,771,136	+$351,307	+25%	01 Oct 2018	31 Dec 2018	10-Q	10 Feb 2020	2020	Q3
Q3 2018	$3,999,779	$542,551	-$72,390	-12%	01 Jul 2018	30 Sep 2018	10-Q	12 Nov 2019	2020	Q2
Q2 2018	$4,072,169	$1,576,399	+$561,339	+55%	01 Apr 2018	30 Jun 2018	10-Q	09 Aug 2019	2020	Q1
Q1 2018	$3,510,830	$461,000	+$289,000	+168%	01 Jan 2018	31 Mar 2018	10-K	14 Jun 2018	2018	FY
Q4 2017	$3,221,830	$1,419,829	-$307,171	-18%	01 Oct 2017	31 Dec 2017	10-Q	11 Feb 2019	2019	Q3
Q3 2017	$3,529,001	$614,941	-$1,236,059	-67%	01 Jul 2017	30 Sep 2017	10-Q	09 Nov 2018	2019	Q2
Q2 2017	$4,765,060	$1,015,060	-$1,132,940	-53%	01 Apr 2017	30 Jun 2017	10-Q	09 Aug 2018	2019	Q1
Q1 2017	$5,898,000	$172,000	-$864,000	-83%	01 Jan 2017	31 Mar 2017	10-K	14 Jun 2018	2018	FY
Q4 2016	$6,762,000	$1,727,000	+$891,000	+107%	01 Oct 2016	31 Dec 2016	10-K	14 Jun 2018	2018	FY
Q3 2016	$5,871,000	$1,851,000	+$436,000	+31%	01 Jul 2016	30 Sep 2016	10-K	14 Jun 2018	2018	FY
Q2 2016	$5,435,000	$2,148,000	+$951,000	+79%	01 Apr 2016	30 Jun 2016	10-K	14 Jun 2018	2018	FY
Q1 2016	$4,484,000	$1,036,000	+$132,000	+15%	01 Jan 2016	31 Mar 2016	10-K	14 Jun 2018	2018	FY
Q4 2015	$4,352,000	$836,000	+$136,000	+19%	01 Oct 2015	31 Dec 2015	10-K	14 Jun 2018	2018	FY
Q3 2015	$4,216,000	$1,415,000	+$733,000	+107%	01 Jul 2015	30 Sep 2015	10-K	14 Jun 2018	2018	FY
Q2 2015	$3,483,000	$1,197,000	+$468,000	+64%	01 Apr 2015	30 Jun 2015	10-K	14 Jun 2018	2018	FY
Q1 2015	$3,015,000	$904,000	-$142,000	-14%	01 Jan 2015	31 Mar 2015	10-K	14 Jun 2017	2017	FY
Q4 2014	$3,157,000	$700,000	-$295,000	-30%	01 Oct 2014	31 Dec 2014	10-K	14 Jun 2017	2017	FY
Q3 2014	$3,452,000	$682,000	+$65,000	+11%	01 Jul 2014	30 Sep 2014	10-K	14 Jun 2017	2017	FY
Q2 2014	$3,387,000	$729,000	+$150,000	+26%	01 Apr 2014	30 Jun 2014	10-K	14 Jun 2017	2017	FY
Q1 2014	$3,237,000	$1,046,000	-$68,367	-6.1%	01 Jan 2014	31 Mar 2014	10-K	15 Jun 2016	2016	FY
Q4 2013	$3,305,367	$995,000	+$728,208	+273%	01 Oct 2013	31 Dec 2013	10-K	15 Jun 2016	2016	FY
Q3 2013	$2,577,159	$617,000	+$137,369	+29%	01 Jul 2013	30 Sep 2013	10-K	15 Jun 2016	2016	FY
Q2 2013	$2,439,790	$579,000	+$124,636	+27%	01 Apr 2013	30 Jun 2013	10-K	15 Jun 2016	2016	FY
Q1 2013	$2,315,154	$1,114,367	+$758,982	+214%	01 Jan 2013	31 Mar 2013	10-K	30 Jun 2014	2014	FY
Q4 2012	$1,556,172	$266,792	+$110,202	+70%	01 Oct 2012	31 Dec 2012	10-Q	14 Feb 2014	2013	Q3
Q3 2012	$1,445,970	$479,631	+$403,300	+528%	01 Jul 2012	30 Sep 2012	10-Q	14 Nov 2013	2013	Q2
Q2 2012	$1,042,670	$454,364	+$28,996	+6.8%	01 Apr 2012	30 Jun 2012	10-Q	14 Aug 2013	2013	Q1
Q1 2012	$1,013,674	$355,385	-$700,914	-66%	01 Jan 2012	31 Mar 2012	10-K	21 Jun 2013	2012	FY
Q4 2011	$1,714,588	$156,590	-$484,934	-76%	01 Oct 2011	31 Dec 2011	10-Q	14 Feb 2013	2012	Q3
Q3 2011	$2,199,522	$76,331	-$489,293	-87%	01 Jul 2011	30 Sep 2011	10-Q	14 Nov 2012	2012	Q2
Q2 2011	$2,688,815	$425,368	+$13,697	+3.3%	01 Apr 2011	30 Jun 2011	10-Q	14 Aug 2012	2012	Q1
Q1 2011	$2,675,118	$1,056,299			01 Jan 2011	31 Mar 2011	10-K	29 Jun 2012	2011	FY
Q4 2010		$641,524			01 Oct 2010	31 Dec 2010	10-Q	14 Feb 2012	2011	Q3
Q3 2010		$565,624			01 Jul 2010	30 Sep 2010	10-Q	14 Nov 2011	2011	Q2
Q2 2010		$411,671			01 Apr 2010	30 Jun 2010	10-Q/A	19 Aug 2011	2011	Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Cost of Revenue (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$43,957,274	+$13,689,249	+45%	01 Apr 2024	31 Mar 2025	10-K	30 Jun 2025	2025	FY
2023	$30,268,025	+$12,706,932	+72%	01 Apr 2023	31 Mar 2024	10-K	30 Jun 2025	2025	FY
2022	$17,561,093	+$94,330	+0.54%	01 Apr 2022	31 Mar 2023	10-K	01 Jul 2024	2024	FY
2021	$17,466,763	+$3,953,152	+29%	01 Apr 2021	31 Mar 2022	10-K	29 Jun 2023	2023	FY
2020	$13,513,611	+$3,497,756	+35%	01 Apr 2020	31 Mar 2021	10-K	29 Jun 2022	2022	FY
2019	$10,015,855	+$5,314,877	+113%	01 Apr 2019	31 Mar 2020	10-K	14 Jun 2021	2021	FY
2018	$4,700,978	+$1,189,855	+34%	01 Apr 2018	31 Mar 2019	10-K	29 Jun 2020	2020	FY
2017	$3,511,123	-$2,387,282	-40%	01 Apr 2017	31 Mar 2018	10-K	21 Jun 2019	2019	FY
2016	$5,898,405	+$1,414,243	+32%	01 Apr 2016	31 Mar 2017	10-K	14 Jun 2018	2018	FY
2015	$4,484,162	+$1,470,570	+49%	01 Apr 2015	31 Mar 2016	10-K	14 Jun 2018	2018	FY
2014	$3,013,592	-$222,514	-6.9%	01 Apr 2014	31 Mar 2015	10-K	14 Jun 2017	2017	FY
2013	$3,236,106	+$920,952	+40%	01 Apr 2013	31 Mar 2014	10-K	15 Jun 2016	2016	FY
2012	$2,315,154	+$1,301,480	+128%	01 Apr 2012	31 Mar 2013	10-K	30 Jun 2014	2014	FY
2011	$1,013,674	-$1,661,444	-62%	01 Apr 2011	31 Mar 2012	10-K	21 Jun 2013	2012	FY
2010	$2,675,118			01 Apr 2010	31 Mar 2011	10-K	29 Jun 2012	2011	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.